

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**EGM**”) of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “**Company**”) will be held at the Company’s conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province, the PRC on Thursday, February 12 2026 at 10:00 a.m. (the “**Meeting**”) for the purposes of considering and, if thought fit, passing the following matter.

SPECIAL RESOLUTION

To consider and, if thought fit, approve:

1. Proposal for granting the general mandate to repurchase H Shares

“**THAT:**

- (a) According to all applicable laws and regulations of the PRC government or securities regulatory authorities, as well as the Hong Kong Stock Exchange, repurchase H Shares on terms deemed appropriate, not exceeding 10% of the total number of issued H Shares (excluding any Treasury Shares) as of the date of this resolution;
- (b) The Board is authorized to make (including but not limited to) the following during the Relevant Period:
 - (i) determine the specific repurchase plan, including but not limited to the repurchase price, number of Shares to be repurchased, repurchase timing and repurchase period, etc.;
 - (ii) open stock accounts and handle the relevant procedures for the repurchase funds, etc.;

- (iii) determine the specific use of the repurchased H Shares in accordance with the actual situation of the Company and to adjust or change such use as permitted by the relevant laws and regulations;
 - (iv) based on market conditions and the capital management needs of the Group at the time of repurchase, decide to cancel such repurchased H Shares or hold such repurchased H Shares as Treasury Shares;
 - (v) if it is decided to cancel the repurchased H Shares, in accordance with the provisions of the Articles of Association, the cancellation procedures for repurchased shares shall be carried out to reduce the registered capital of the Company, and the Articles of Association shall be amended as it deems appropriate and necessary to reflect the reduction of the registered capital of the Company; and
 - (vi) take any other necessary actions and complete any necessary procedures to repurchase such shares in accordance with paragraph (a) of this special resolution.
- (c) For the purpose of this special resolution, “Relevant Period” refers to the period from the date of its adoption to the earliest of the following:
- (i) at the conclusion of the next annual general meeting of the Company after the passing of this resolution;
 - (ii) the date on which the next annual general meeting of the Company is required to be held by the Articles of Association or other applicable laws; or
 - (iii) the date on which the Shareholders pass a special resolution at the Shareholders’ meeting to revoke or amend the authorization granted to the Board as stated in this resolution.”

Yours faithfully,
For and on behalf of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, January 27, 2026

As at the date of this notice, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qionggang as independent non-executive Directors.

Notes:

1. Unless otherwise indicated, capitalized terms used herein shall have the same meaning as those defined in the circular of the Company dated January 27, 2026.
2. For details of the proposal for granting the general mandate to repurchase H Shares, please refer to the accompanying circular.
3. In order to determine the Shareholders who are entitled to attend the EGM, the register of members of the Company will be closed from February 9, 2026 to February 12, 2026, both days inclusive, during which no transfer of Shares will be registered.

To be entitled to attend and vote at the EGM, Shareholders whose transfer of Shares have not been registered must lodge all transfer instruments accompanied by the relevant share certificates with the Company's H Shares registrar and transfer office, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration at or before 4:30 p.m. on February 6, 2026 (Hong Kong time).

4. Shareholders of the Company whose names appear on the register of members of the Company on February 12, 2026 will be entitled to attend and vote at the EGM or any adjourned meetings.
5. If a Shareholder appoints more than one proxy to attend the meeting, its proxy can only vote by poll.
6. Shareholders who have the right to attend and vote at the EGM are entitled to appoint one or more proxies (whether or not a Shareholder) to attend and vote on his/her/its behalf. For those Shareholders who appoint more than one proxy, such proxies can only exercise their voting rights by way of poll. Shareholders who intend to appoint one or more proxies should first read the accompanying circular.
7. If a proxy is appointed to attend the EGM on behalf of a Shareholder, the proxy must produce proof of identity and the authorisation instrument with the date of issue and duly signed by the proxy or its legal personal representative, and in the case of legal representatives of legal person Shareholders, such legal representatives must produce proof of identity and effective document to identify its identity as legal representative. If a legal person Shareholder appoints a company representative other than its legal representative to attend the EGM, such representative must produce proof of identity and the authorisation instrument bearing the company chop of the legal person Shareholder and duly authorised by its legal representative.
8. If the proxy form is signed by a person under a power of attorney or other authority, the power of attorney or other authority must be notarially certified. In order to be valid, the notarially certified copy of such power of attorney or other authority under which it is signed together with the proxy form must be deposited not less than 24 hours before the time for holding the EGM at the H Shares registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.
9. The EGM is expected to be held for less than half a day. Shareholders and their proxies who attend the meeting shall arrange for their own transportation and accommodation at their own expenses.